Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT04417985 Completed - Clinical trials for Nasopharyngeal Carcinoma

Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma

Start date: August 1, 2011
Phase: N/A
Study type: Interventional

Nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies terms of its epidemiology, pathology, and treatment outcome. Although NPC is a radiosensitive tumor, distant recurrence remains a clinical challenge. Therefore, the investigators conducted this study to prospectively investigate the role of imaging and blood biomarkers in predicting the prognosis of NPC patients.

NCT ID: NCT04416516 Completed - Clinical trials for Basal Cell Carcinoma

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Start date: July 16, 2020
Phase: Phase 2
Study type: Interventional

The primary objectives are to: 1. Evaluate the safety and tolerability of intralesional ASN-002 when administered in combination with oral vismodegib in patients with Basal Cell Carcinomas (BCC)s; 2. Evaluate the efficacy of intralesional ASN-002 in target tumours when administered in combination with oral vismodegib in patients with BCCs. The secondary objective is to: 1) Evaluate the efficacy of intralesional ASN-002 in non-target tumours when administered in combination with oral vismodegib in patients with BCCs. The exploratory objective is to: 1) Evaluate immunological biomarkers during the course of treatment.

NCT ID: NCT04415567 Completed - Clinical trials for Hepatocellular Carcinoma

Adjuvant Lenvatinib Prevents Recurrence of High-risk Patients With HBV-related HCC After Liver Transplantation

Start date: June 1, 2018
Phase:
Study type: Observational

High-risk patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) suffer from a high ratio of recurrence after liver transplantation (LT). Lenvatinib, as a novel targeted drug, has shown an excellent effect in the treatment of advanced HCC, but there is no study on its effect in preventing HCC recurrence in the patients undergoing transplantation. Therefore, to evaluate the role of adjuvant lenvatinib in preventing recurrence of high-risk LT recipients with HBV-related HCC, the investigators retrospectively analyzed 23 high-risk patients consisting of lenvatinib group (n=14) and control group (n=9) with HBV-related HCC who underwent LT. Disease-free survival (DFS) and HCC recurrence of the two groups were compared. The adverse events (AEs) and drug tolerance of lenvatinib were evaluated.

NCT ID: NCT04413214 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial

Start date: December 20, 2019
Phase: Phase 1
Study type: Interventional

The trial is a study conducted to evaluate the safety, tolerability and PK characteristics of Carrimycin tablet and measure its anti-tumor efficacy initially in the treatment of patients with locally advanced, recurrent, or metastatic head and neck squamous cell carcinoma (non NPC).

NCT ID: NCT04412161 Completed - Clinical trials for Hepatocellular Carcinoma

Liver Transplant for Larger Hepatocellular Carcinoma in Malatya: The Role of GGT and AFP

Start date: April 19, 2006
Phase:
Study type: Observational

Retrospective data on 50 prospectively-collected HCC patients with beyond-Milan criteria with >6cm tumors were analyzed. 5-year OS of 76.2% was found in patients with both AFP <200 ng/ml and GGT <104 IU/mL with tumors less than 10 cm diameter. Thus, GGT values add to AFP in patient prognosis.

NCT ID: NCT04402749 Completed - Clinical trials for Renal Cell Carcinoma

The Incidence of Pulmonary Embolism During Nephrectomy

Start date: October 1, 2020
Phase:
Study type: Observational

Patients with renal carcinoma was reported at high incidence of perioperative pulmonary embolism from current study. The investigators aimed to determine the incidence and outcome of this group of patient in the tertiary-care, university hospital and the rate of intraoperative transesophageal echocardiography utility and outcome.

NCT ID: NCT04401800 Completed - Clinical trials for Hepatocellular Carcinoma

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

Start date: September 4, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

NCT ID: NCT04397341 Completed - Clinical trials for Locally Advanced Head and Neck Carcinoma

Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck

Start date: March 1, 2014
Phase: Phase 2
Study type: Interventional

This study aimed to assess the efficacy and safety for biweekly TPF as induction chemotherapy for locally advanced head and neck cancer

NCT ID: NCT04396886 Completed - Metastatic Cancer Clinical Trials

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Start date: February 27, 2020
Phase: Phase 2
Study type: Interventional

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).

NCT ID: NCT04394065 Completed - Clinical trials for Nasopharyngeal Carcinoma

uEXPLORER Total-body PET/CT in Nasopharyngeal Carcinoma

Start date: June 20, 2020
Phase:
Study type: Observational [Patient Registry]

uEXPLORER total-body PET/CT in Nasopharyngeal Carcinoma